Anson Funds Management LP Sellas Life Sciences Group, Inc. Transaction History
Anson Funds Management LP
- $542 Million
- Q2 2025
A detailed history of Anson Funds Management LP transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Anson Funds Management LP holds 275,000 shares of SLS stock, worth $415,250. This represents 0.11% of its overall portfolio holdings.
Number of Shares
275,000
Previous 7,579,095
96.37%
Holding current value
$415,250
Previous $8.19 Million
92.65%
% of portfolio
0.11%
Previous 1.95%
Shares
5 transactions
Others Institutions Holding SLS
# of Institutions
96Shares Held
23.5MCall Options Held
1.3MPut Options Held
59.3K-
Vanguard Group Inc Valley Forge, PA6.84MShares$10.3 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.72MShares$4.1 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$3.32 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.49MShares$2.25 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.13MShares$1.7 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $31M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...